Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

Gaitan-Duarte (Emtricitabine/Tenofovir), 2021 NCT04359095

tenofovir/emtricitabine (n=163) vs. standard of care (n=162)

randomized controlled trial   some concerns about risk of bias

Studied treatment

Emtricitabine/tenofovir
emtricitabine(200 mg) tenofovir disoproxil (300 mg), once a day for 10 days PO,

Control treatment

Standard of care

The standard of care follows the recommendations of the Colombian Consensus forCovid-19 Treatment in Hospitalized Patients,21 consisting of the use of dexamethasone,antiparasitic treatment (ivermectin or albendazole), enoxaparin, acetaminophen, oxygen asneeded, and supportive treatment for organ failure (i.e., use mechanical ventilation, ordialysis).

Patients

COVID 19 hospitalized

Adults aged 18 years or more, with a positive real-time polymerase chain reaction (RT-PCR) or with high suspicion of SARS CoV-2 by clinical criteria and a diagnosis of mild, severe, or critical pneumonia, requiring hospital management in six high complexity referral hospitals located in Bogota.

Method

Open-label.

6 hospitals in Bogota, Colombia.

Remark

Relative Risks adjusted for age, sex, and severity of pneumonia using g Log-binomial General Estimating Equation models, assuming exchangeable correlation structure with each center as a cluster.